Determination of 5-Fluorouracil in Plasma with HPLC-Tandem Mass Spectrometry
- 1 June 2006
- journal article
- research article
- Published by Taylor & Francis in Nucleosides, Nucleotides & Nucleic Acids
- Vol. 25 (9-11) , 1257-1260
Abstract
In this article, we describe a fast and specific method to measure 5FU with HPLC tandem-mass spectrometry. Reversed-phase HPLC was combined with electrospray ionization tandem mass spectrometry and detection was performed by multiple-reaction monitoring. Stable-isotope-labeled 5FU (1,3–15N2–5FU) was used as an internal standard. 5FU was measured within a single analytical run of 16 min with a lower limit of detection of 0.05 μM. The intra-assay variation and inter-assay variation of plasma with added 5FU (1 μM, 10 μM, 100 μM) was less then 6%. Recoveries of the added 5FU in plasma were > 97%. Analysis of the 5FU levels in plasma samples from patients with the HPLC tandem mass spectrometry method and a HPLC-UV method yielded comparable results (r2 = 0.98). Thus, HPLC with electrospray ionization tandem mass spectrometry allows the rapid analysis of 5FU levels in plasma and could, therefore, be used for therapeutic drug monitoring.Keywords
This publication has 3 references indexed in Scilit:
- A Simple and Sensitive Fully Validated HPLC-UV Method for the Determination of 5-Fluorouracil and Its Metabolite 5,6-Dihydrofluorouracil in PlasmaTherapeutic Drug Monitoring, 2005
- Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracilEuropean Journal of Cancer, 2004
- Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD geneBritish Journal of Cancer, 2002